Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 6/20 | 0.39 |
| ▸ | CA2 | P00918 | 6/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22904407 | 0.96 | DRD2 (0.42) | DRD2SIGMAR1NAMPTCA1CA2 | |
| SCHEMBL22904279 | 0.96 | DRD2 (0.42) | DRD2SIGMAR1NAMPTCA1CA2 | |
| SCHEMBL22904277 | 0.96 | DRD2 (0.42) | DRD2SIGMAR1NAMPTCA1CA2 | |
| SCHEMBL22904101 | 0.91 | DRD2 (0.42) | DRD2SIGMAR1NAMPTMAPT | |
| SCHEMBL22904413 | 0.88 | DRD2 (0.41) | DRD2SIGMAR1MAPT | |
| SCHEMBL22904411 | 0.88 | DRD2 (0.41) | DRD2SIGMAR1MAPT | |
| SCHEMBL22904098 | 0.88 | DRD2 (0.41) | DRD2SIGMAR1MAPT | |
| SCHEMBL22904408 | 0.85 | DRD2 (0.42) | DRD2CA1CA2CA12CA9 | |
| SCHEMBL22904409 | 0.84 | DRD2 (0.41) | DRD2CA1CA2CA12CA9 | |
| SCHEMBL22904571 | 0.83 | DRD2 (0.46) | DRD2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021011631-A1 | FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |